首頁 > 市場調查報告書 > 醫療設備

婦科治療

市場調查報告書

商品編碼

1777649

全球子宮肌瘤治療藥物市場

Uterine Fibroid Treatment Drugs

出版日期: 2025年07月28日 | 出版商:

Global Industry Analysts, Inc. | 英文 376 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

到 2030 年，全球子宮肌瘤藥物市場規模將達到 36 億美元

2024年全球子宮肌瘤藥物市場規模估計為21億美元，預計在分析期內（2024-2030年）將以9.0%的複合年成長率成長，到2030年將達到36億美元。本報告分析的細分市場之一—促性腺激素分泌釋放激素促效劑，預計其複合年成長率將達到10.4%，到分析期末達到14億美元。促性腺激素分泌釋放激素拮抗劑細分市場在分析期間內的複合年成長率估計為6.8%。

美國市場規模估計為 5.777 億美元，中國市場預計複合年成長率為 14.2%

美國子宮肌瘤藥物市場規模預計在2024年達到5.777億美元。作為世界第二大經濟體，中國預計到2030年市場規模將達到7.893億美元，在2024-2030年的分析期間內，複合年成長率為14.2%。其他值得關注的區域市場包括日本和加拿大，預計在分析期間內，這兩個市場的複合年成長率分別為4.5%和8.6%。在歐洲，預計德國市場的複合年成長率約為6.1%。

全球子宮肌瘤藥物市場－主要趨勢與促進因素摘要

子宮肌瘤盛行率的不斷上升是否會改變藥物治療的需求？

子宮肌瘤（平滑肌瘤）是育齡婦女最常見的良性腫瘤之一，全球盛行率估計接近 20% 至 40%。隨著人們認知的提高、診斷的改進以及醫療保健可及性的改善，尋求治療子宮肌瘤相關症狀（包括月經過多、骨盆疼痛、不孕症和貧血）的婦女數量顯著增加。由於許多患者尋求子宮切除術和肌瘤摘除等侵入性手術的治療方法，藥物治療正逐漸流行起來。患者偏好的這種轉變顯著擴大了對肌瘤藥物作為第一線或術前治療選擇的需求。子宮肌瘤最常影響 30 多歲和 40 多歲的女性，其中許多人仍處於生育年齡。因此，保持生育能力和避免漫長的恢復期是核心關注點，這進一步推動了對有效的非手術治療方法的需求。種族差異，尤其是非裔女性較高的發生率和嚴重程度，也導致了醫療資源匱乏和高風險族群中子宮肌瘤的發生率上升。這些人口統計和臨床趨勢為子宮肌瘤藥物治療領域的持續發展奠定了堅實的基礎。

新型藥物和荷爾蒙如何推動治療方案的進步？

藥物創新正在迅速改變子宮肌瘤治療的格局，新型改良藥物能夠更好地控制症狀、減少副作用並提高治療便利性。促性腺激素分泌釋放激素 (GnRH) 類似物長期以來一直用於縮小子宮肌瘤並控制大量出血，但由於骨質流失和潮熱等低雌激素副作用，其長期使用受到限制。這為提供更有針對性的荷爾蒙控制且安全性更高的新治療方法鋪平了道路，例如選擇性孕激素受體調變器(SPRM) 和口服 GnRH 拮抗劑。利高利 (rilgolix) 等藥物通常與雌二醇或炔諾酮聯合使用，如今正成為有效的口服療法，兼具療效和患者耐受性。這些新型藥物能夠長期控制症狀，並且擴大被用作手術干預的替代或輔助手段。同時，緩釋性和聯合治療等藥物傳遞機制的進步正在提高患者的依從性，並擴大個人化治療方案。子宮肌瘤治療的藥物研發管線比以往任何時候都更加活躍，目前正在進行的臨床試驗正在探索新的荷爾蒙調節、抗纖維化甚至免疫調節療法。這些創新不僅改善了治療效果，也強化了市場向個人化、非侵入性子宮肌瘤治療的轉變。

病患偏好和醫療模式的改變是否推動了非手術治療的採用？

全球對以患者為中心的微創治療的重視正在從根本上改變子宮肌瘤的治療方式。越來越多的女性正在尋求治療方法方法。這使得藥物治療成為一種頗具吸引力的選擇，尤其對於症狀輕微至中度的患者以及等待手術的患者而言。此外，不斷發展的門診護理模式和遠端醫療平台的擴展促進了遠距離診斷、追蹤和肌瘤藥物的處方，使資源匱乏的地區更容易獲得治療。直銷健康平台和數位健康品牌也在揭開月經健康和子宮肌瘤的神秘面紗，鼓勵更多女性儘早尋求治療方面發揮作用。此外，將藥物治療與其他非侵入性手術（例如子宮動脈栓塞術 (UAE) 和聚焦超音波手術 (FUS)）相結合，為患者和醫療保健提供者在治療計劃方面提供了更大的靈活性。為此，製藥公司越來越注重教育、病患支持計畫和社區推廣，以提高依從性並改善治療效果。這種以患者主導的勢頭正在促進更加多樣化和包容性的市場環境，在這種環境中，藥物既可以作為獨立的解決方案，也可以作為更廣泛的多治療策略的組成部分。

哪些因素將推動子宮肌瘤藥物市場的長期成長？

子宮肌瘤治療市場的成長受到臨床需求、技術進步、患者人口結構變化和醫療保健服務體係不斷發展的共同驅動。一個關鍵促進因素是全球子宮肌瘤盛行率的上升，尤其是在 30 至 50 歲的女性中，她們非常積極主動地尋求治療並保持生殖健康。標靶荷爾蒙療法的不斷擴大，包括 SPRM 和口服 GnRH 拮抗劑，為長期管理提供了更安全、更便捷的選擇，引起了患者和醫療保健提供者的濃厚興趣。此外，世界各地的醫療保健系統正在轉向非手術治療慢性病，為藥物治療子宮肌瘤創造了有利環境。此外，不斷加強的宣傳宣傳活動和婦女健康倡導工作正在改善教育並減少圍繞月經健康的恥辱感，從而實現早期診斷並增加對藥物治療解決方案的需求。美國、歐洲和日本等主要市場的報銷核准和監管認可也提升了產品的可及性和商業性可行性。大型製藥公司和生技企業的投資正在推動研發，而數位健康平台則促進了更廣泛的分銷和病患參與。這些因素共同推動了子宮肌瘤治療市場的持續成長，而這得益於技術創新、可及性和日益壯大的全球患者群體。

部分

依藥物類別（促性腺激素分泌釋放激素促效劑、促性腺激素分泌釋放激素拮抗劑、孕激素釋放子宮內避孕器/避孕藥、非荷爾蒙藥物等）、按類型（漿膜下子宮肌瘤、漿膜內子宮肌瘤、黏膜下子宮肌瘤、帶蒂子宮肌瘤）和最終用戶（醫院藥房、零售藥房等）

受訪公司範例

AbbVie Inc.
Abbott Healthcare Pvt. Ltd.
Amring Pharmaceuticals Inc.
AstraZeneca
Bayer AG
Biocon Biologics
Bristol-Myers Squibb Company
Ferring Pharmaceuticals
Gedeon Richter plc
GlaxoSmithKline plc
Hologic, Inc.
Hoffmann-La Roche Ltd
Ipsen Pharma
Kissei Pharmaceutical Co., Ltd.
Medtronic
Merot Medical Systems
Minerva Surgical, Inc.
Myovant Sciences GmbH
Novartis AG
ObsEva

人工智慧整合

全球產業分析師利用可操作的專家內容和人工智慧工具改變市場和競爭情報。

Global Industry Analysts 沒有遵循典型的 LLM 或特定於行業的 SLM查詢，而是建立了一個從世界各地的專家收集的內容庫，其中包括影片錄像、BLOG、搜尋引擎研究以及大量的公司、產品/服務和市場數據。

關稅影響係數

全球產業分析師根據公司總部所在國家、製造地以及進出口情況（成品和原始OEM）預測其競爭地位的變化。這種複雜多變的市場動態預計將以多種方式影響競爭對手，包括銷貨成本(COGS) 上升、盈利下降、供應鏈重組以及其他微觀和宏觀市場動態。

The global market for Uterine Fibroid Treatment Drugs estimated at US$2.1 Billion in the year 2024, is expected to reach US$3.6 Billion by 2030, growing at a CAGR of 9.0% over the analysis period 2024-2030. Gonadotropin-releasing Hormone Agonists, one of the segments analyzed in the report, is expected to record a 10.4% CAGR and reach US$1.4 Billion by the end of the analysis period. Growth in the Gonadotropin-releasing Hormone Antagonists segment is estimated at 6.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$577.7 Million While China is Forecast to Grow at 14.2% CAGR

The Uterine Fibroid Treatment Drugs market in the U.S. is estimated at US$577.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$789.3 Million by the year 2030 trailing a CAGR of 14.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.5% and 8.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.1% CAGR.

Global Uterine Fibroid Treatment Drugs Market - Key Trends & Drivers Summarized

Is the Rising Prevalence of Uterine Fibroids Reshaping the Demand for Drug-Based Therapies?

Uterine fibroids, or leiomyomas, are one of the most common benign tumors in women of reproductive age, with an estimated global prevalence affecting nearly 20% to 40% of women. The rising awareness, improved diagnosis, and increased healthcare access have significantly boosted the number of women seeking treatment for fibroid-related symptoms such as heavy menstrual bleeding, pelvic pain, infertility, and anemia. As many patients look for alternatives to invasive surgical procedures such as hysterectomy and myomectomy, pharmaceutical interventions are gaining renewed traction. This shift in patient preference has significantly expanded the demand for uterine fibroid treatment drugs as first-line or pre-surgical management options. With fibroids more commonly affecting women in their 30s and 40s-many of whom are still in their childbearing years-preserving fertility and avoiding long recovery times has become a central concern, further propelling the need for effective, non-surgical therapies. Ethnic disparities particularly higher incidence and severity among women of African descent are also contributing to a growing patient pool in underserved and high-risk communities. These demographic and clinical dynamics are creating a robust foundation for sustained growth in the drug-based treatment segment for uterine fibroids.

How Are Novel Drug Classes and Hormonal Agents Advancing Therapeutic Options?

Pharmaceutical innovation is rapidly transforming the landscape of uterine fibroid treatment, with new and improved drugs offering enhanced symptom control, fewer side effects, and greater convenience. Gonadotropin-releasing hormone (GnRH) analogs have long been used to reduce fibroid size and manage heavy bleeding, but their association with hypoestrogenic side effects like bone loss and hot flashes has limited long-term use. This has paved the way for newer therapies such as selective progesterone receptor modulators (SPRMs) and oral GnRH antagonists, which offer more targeted hormonal modulation with improved safety profiles. Drugs like relugolix, often used in combination with estradiol and norethindrone, are now emerging as effective oral therapies that balance efficacy with patient tolerability. These novel agents are enabling long-term symptom management and are increasingly being prescribed as alternatives or adjuncts to surgical intervention. In parallel, advancements in drug delivery mechanisms-such as extended-release formulations and combination therapies-are enhancing patient adherence and expanding options for individualized care. With ongoing clinical trials exploring new hormone regulators, anti-fibrotic agents, and even immune-modulating therapies, the pharmaceutical pipeline for uterine fibroid treatment is more dynamic than ever. These innovations are not only improving therapeutic outcomes but are also reinforcing the market’s shift toward personalized, non-invasive fibroid management.

Are Shifting Patient Preferences and Healthcare Models Driving Non-Surgical Treatment Adoption?

The growing global emphasis on patient-centered, minimally invasive care is fundamentally changing how uterine fibroids are managed-putting greater focus on drug-based interventions. Increasingly, women are demanding treatment options that allow them to preserve their uterus, maintain fertility, and avoid extended downtime associated with surgery. This has made pharmacological therapies an attractive choice, particularly for those with mild to moderate symptoms or those awaiting surgery. Moreover, the evolution of outpatient care models and the expansion of telemedicine platforms are facilitating remote diagnosis, follow-up, and prescription of fibroid treatment drugs, making therapies more accessible even in lower-resource settings. Direct-to-consumer health platforms and digital wellness brands are also playing a role in demystifying menstrual health and fibroid awareness, encouraging more women to pursue medical treatment earlier. Furthermore, the ability to combine drug therapy with other non-invasive procedures, such as uterine artery embolization (UAE) or focused ultrasound surgery (FUS), is giving patients and providers more flexibility in treatment planning. In response, pharmaceutical companies are increasingly focusing on education, patient support programs, and community outreach to encourage adherence and improve outcomes. This patient-driven momentum is contributing to a more diversified and inclusive market landscape, where drug therapies serve as both standalone solutions and components of broader multimodal treatment strategies.

What Factors Are Driving Long-Term Growth in the Uterine Fibroid Treatment Drugs Market?

The growth in the uterine fibroid treatment drugs market is driven by a combination of clinical need, technological progress, changing patient demographics, and evolving healthcare delivery systems. A key driver is the increasing global prevalence of fibroids, particularly among women aged 30 to 50, a demographic that is highly active in seeking care and maintaining reproductive health. The expanding pipeline of targeted hormonal therapies, including SPRMs and oral GnRH antagonists, is providing safer, more convenient options for long-term management, thus drawing greater interest from both patients and providers. Healthcare systems around the world are also shifting toward non-surgical management of chronic conditions, creating a favorable environment for the adoption of drug-based fibroid therapies. Additionally, growing awareness campaigns and women's health advocacy efforts are improving education and reducing stigma around menstrual health, leading to earlier diagnosis and greater demand for pharmacologic solutions. Reimbursement approvals and regulatory endorsements in key markets like the U.S., Europe, and Japan are also bolstering product accessibility and commercial viability. Investment from major pharmaceutical companies and biotech startups alike is fueling research and development, while digital health platforms are enabling broader distribution and patient engagement. Together, these factors are ensuring that the uterine fibroid treatment drugs market continues to grow, driven by innovation, accessibility, and an increasingly empowered global patient population.

SCOPE OF STUDY:

The report analyzes the Uterine Fibroid Treatment Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications, Others); Type (Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids, Pedunculated Fibroids); End-User (Hospital Pharmacies, Retail Pharmacies, Others)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

AbbVie Inc.
Abbott Healthcare Pvt. Ltd.
Amring Pharmaceuticals Inc.
AstraZeneca
Bayer AG
Biocon Biologics
Bristol-Myers Squibb Company
Ferring Pharmaceuticals
Gedeon Richter plc
GlaxoSmithKline plc
Hologic, Inc.
Hoffmann-La Roche Ltd
Ipsen Pharma
Kissei Pharmaceutical Co., Ltd.
Medtronic
Merot Medical Systems
Minerva Surgical, Inc.
Myovant Sciences GmbH
Novartis AG
ObsEva

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
- Influencer Market Insights
- Tariff Impact on Global Supply Chain Patterns
- Uterine Fibroid Treatment Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
- Rising Global Prevalence of Uterine Fibroids Spurs Sustained Demand for Drug-Based Treatment Alternatives
- Increased Preference for Fertility-Preserving and Non-Surgical Therapies Strengthens Business Case for Pharmacologic Options
- Advancements in Hormonal Drug Classes and Targeted Therapies Propel Innovation in Symptom Management
- Growing Patient Awareness and Early Diagnosis Trends Expand the Addressable Market for Medical Treatment
- Shift Toward Personalized Medicine and Symptom-Specific Formulations Drives Adoption Among Reproductive-Age Women
- Postponement of Childbearing and Changing Reproductive Health Trends Fuel Demand for Uterus-Conserving Therapies
- Regulatory Approvals and Market Entry of Oral GnRH Antagonists Create New Competitive Opportunities
- Expansion of Telehealth and Direct-to-Consumer Gynecology Services Accelerates Access to Treatment Options
- Rising Investments in Women's Health Research and Drug Development Strengthen the Therapeutic Pipeline
- Increased Emphasis on Quality of Life and Menstrual Health Throws Spotlight on Long-Term Medical Management Solutions
- Combination Therapy Approaches Generate Opportunities for Multifaceted and Extended Treatment Plans
- Digital Education Campaigns and Advocacy Efforts Drive Patient Engagement and Reduce Stigma Around Fibroid Management
4. GLOBAL MARKET PERSPECTIVE
- TABLE 1: World Uterine Fibroid Treatment Drugs Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
- TABLE 2: World Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 3: World Historic Review for Uterine Fibroid Treatment Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 4: World 15-Year Perspective for Uterine Fibroid Treatment Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
- TABLE 5: World Recent Past, Current & Future Analysis for Gonadotropin-releasing Hormone Agonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 6: World Historic Review for Gonadotropin-releasing Hormone Agonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 7: World 15-Year Perspective for Gonadotropin-releasing Hormone Agonists by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 8: World Recent Past, Current & Future Analysis for Gonadotropin-releasing Hormone Antagonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 9: World Historic Review for Gonadotropin-releasing Hormone Antagonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 10: World 15-Year Perspective for Gonadotropin-releasing Hormone Antagonists by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 11: World Recent Past, Current & Future Analysis for Progestin-releasing Intrauterine Device & Contraceptives by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 12: World Historic Review for Progestin-releasing Intrauterine Device & Contraceptives by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 13: World 15-Year Perspective for Progestin-releasing Intrauterine Device & Contraceptives by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 14: World Recent Past, Current & Future Analysis for Non-hormonal Medications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 15: World Historic Review for Non-hormonal Medications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 16: World 15-Year Perspective for Non-hormonal Medications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 17: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 18: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 19: World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 20: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 21: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 22: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 23: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 24: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 25: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 26: World Recent Past, Current & Future Analysis for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 27: World Historic Review for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 28: World 15-Year Perspective for Other End-Users by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 29: World Recent Past, Current & Future Analysis for Subserosal Fibroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 30: World Historic Review for Subserosal Fibroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 31: World 15-Year Perspective for Subserosal Fibroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 32: World Recent Past, Current & Future Analysis for Intramural Fibroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 33: World Historic Review for Intramural Fibroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 34: World 15-Year Perspective for Intramural Fibroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 35: World Recent Past, Current & Future Analysis for Submucosal Fibroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 36: World Historic Review for Submucosal Fibroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 37: World 15-Year Perspective for Submucosal Fibroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 38: World Recent Past, Current & Future Analysis for Pedunculated Fibroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 39: World Historic Review for Pedunculated Fibroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 40: World 15-Year Perspective for Pedunculated Fibroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

UNITED STATES
- Uterine Fibroid Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
- TABLE 41: USA Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 42: USA Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 43: USA 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 44: USA Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 45: USA Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 46: USA 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
- TABLE 47: USA Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 48: USA Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 49: USA 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
CANADA
- TABLE 50: Canada Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 51: Canada Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 52: Canada 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 53: Canada Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 54: Canada Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 55: Canada 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
- TABLE 56: Canada Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 57: Canada Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 58: Canada 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
JAPAN
- Uterine Fibroid Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
- TABLE 59: Japan Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 60: Japan Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 61: Japan 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 62: Japan Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 63: Japan Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 64: Japan 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
- TABLE 65: Japan Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 66: Japan Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 67: Japan 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
CHINA
- Uterine Fibroid Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
- TABLE 68: China Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 69: China Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 70: China 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 71: China Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 72: China Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 73: China 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
- TABLE 74: China Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 75: China Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 76: China 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
EUROPE
- Uterine Fibroid Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
- TABLE 77: Europe Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 78: Europe Historic Review for Uterine Fibroid Treatment Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 79: Europe 15-Year Perspective for Uterine Fibroid Treatment Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
- TABLE 80: Europe Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 81: Europe Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 82: Europe 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 83: Europe Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 84: Europe Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 85: Europe 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
- TABLE 86: Europe Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 87: Europe Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 88: Europe 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
FRANCE
- Uterine Fibroid Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
- TABLE 89: France Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 90: France Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 91: France 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 92: France Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 93: France Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 94: France 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
- TABLE 95: France Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 96: France Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 97: France 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
GERMANY
- Uterine Fibroid Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
- TABLE 98: Germany Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 99: Germany Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 100: Germany 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 101: Germany Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 102: Germany Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 103: Germany 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
- TABLE 104: Germany Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 105: Germany Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 106: Germany 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
ITALY
- TABLE 107: Italy Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 108: Italy Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 109: Italy 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 110: Italy Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 111: Italy Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 112: Italy 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
- TABLE 113: Italy Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 114: Italy Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 115: Italy 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
UNITED KINGDOM
- Uterine Fibroid Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
- TABLE 116: UK Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 117: UK Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 118: UK 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 119: UK Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 120: UK Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 121: UK 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
- TABLE 122: UK Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 123: UK Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 124: UK 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
SPAIN
- TABLE 125: Spain Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 126: Spain Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 127: Spain 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 128: Spain Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 129: Spain Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 130: Spain 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
- TABLE 131: Spain Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 132: Spain Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 133: Spain 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
RUSSIA
- TABLE 134: Russia Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 135: Russia Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 136: Russia 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 137: Russia Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 138: Russia Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 139: Russia 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
- TABLE 140: Russia Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 141: Russia Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 142: Russia 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
REST OF EUROPE
- TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 144: Rest of Europe Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 145: Rest of Europe 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 147: Rest of Europe Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 148: Rest of Europe 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
- TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 150: Rest of Europe Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 151: Rest of Europe 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
ASIA-PACIFIC
- Uterine Fibroid Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
- TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 153: Asia-Pacific Historic Review for Uterine Fibroid Treatment Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 154: Asia-Pacific 15-Year Perspective for Uterine Fibroid Treatment Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
- TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 156: Asia-Pacific Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 157: Asia-Pacific 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 159: Asia-Pacific Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 160: Asia-Pacific 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
- TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 162: Asia-Pacific Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 163: Asia-Pacific 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
AUSTRALIA
- Uterine Fibroid Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
- TABLE 164: Australia Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 165: Australia Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 166: Australia 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 167: Australia Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 168: Australia Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 169: Australia 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
- TABLE 170: Australia Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 171: Australia Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 172: Australia 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
INDIA
- Uterine Fibroid Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
- TABLE 173: India Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 174: India Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 175: India 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 176: India Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 177: India Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 178: India 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
- TABLE 179: India Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 180: India Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 181: India 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
SOUTH KOREA
- TABLE 182: South Korea Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 183: South Korea Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 184: South Korea 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 185: South Korea Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 186: South Korea Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 187: South Korea 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
- TABLE 188: South Korea Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 189: South Korea Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 190: South Korea 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
REST OF ASIA-PACIFIC
- TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 192: Rest of Asia-Pacific Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 195: Rest of Asia-Pacific Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 196: Rest of Asia-Pacific 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
- TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 198: Rest of Asia-Pacific Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 199: Rest of Asia-Pacific 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
LATIN AMERICA
- Uterine Fibroid Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
- TABLE 200: Latin America Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 201: Latin America Historic Review for Uterine Fibroid Treatment Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 202: Latin America 15-Year Perspective for Uterine Fibroid Treatment Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
- TABLE 203: Latin America Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 204: Latin America Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 205: Latin America 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 206: Latin America Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 207: Latin America Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 208: Latin America 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
- TABLE 209: Latin America Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 210: Latin America Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 211: Latin America 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
ARGENTINA
- TABLE 212: Argentina Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 213: Argentina Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 214: Argentina 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 215: Argentina Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 216: Argentina Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 217: Argentina 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
- TABLE 218: Argentina Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 219: Argentina Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 220: Argentina 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
BRAZIL
- TABLE 221: Brazil Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 222: Brazil Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 223: Brazil 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 224: Brazil Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 225: Brazil Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 226: Brazil 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
- TABLE 227: Brazil Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 228: Brazil Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 229: Brazil 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
MEXICO
- TABLE 230: Mexico Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 231: Mexico Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 232: Mexico 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 233: Mexico Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 234: Mexico Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 235: Mexico 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
- TABLE 236: Mexico Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 237: Mexico Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 238: Mexico 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
REST OF LATIN AMERICA
- TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 240: Rest of Latin America Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 241: Rest of Latin America 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 243: Rest of Latin America Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 244: Rest of Latin America 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
- TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 246: Rest of Latin America Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 247: Rest of Latin America 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
MIDDLE EAST
- Uterine Fibroid Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
- TABLE 248: Middle East Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 249: Middle East Historic Review for Uterine Fibroid Treatment Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 250: Middle East 15-Year Perspective for Uterine Fibroid Treatment Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
- TABLE 251: Middle East Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 252: Middle East Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 253: Middle East 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 254: Middle East Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 255: Middle East Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 256: Middle East 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
- TABLE 257: Middle East Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 258: Middle East Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 259: Middle East 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
IRAN
- TABLE 260: Iran Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 261: Iran Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 262: Iran 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 263: Iran Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 264: Iran Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 265: Iran 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
- TABLE 266: Iran Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 267: Iran Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 268: Iran 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
ISRAEL
- TABLE 269: Israel Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 270: Israel Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 271: Israel 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 272: Israel Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 273: Israel Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 274: Israel 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
- TABLE 275: Israel Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 276: Israel Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 277: Israel 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
SAUDI ARABIA
- TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 279: Saudi Arabia Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 280: Saudi Arabia 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 282: Saudi Arabia Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 283: Saudi Arabia 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
- TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 285: Saudi Arabia Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 286: Saudi Arabia 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
UNITED ARAB EMIRATES
- TABLE 287: UAE Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 288: UAE Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 289: UAE 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 290: UAE Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 291: UAE Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 292: UAE 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
- TABLE 293: UAE Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 294: UAE Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 295: UAE 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
REST OF MIDDLE EAST
- TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 297: Rest of Middle East Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 298: Rest of Middle East 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 300: Rest of Middle East Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 301: Rest of Middle East 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
- TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 303: Rest of Middle East Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 304: Rest of Middle East 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
AFRICA
- Uterine Fibroid Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
- TABLE 305: Africa Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 306: Africa Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 307: Africa 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 308: Africa Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 309: Africa Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 310: Africa 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
- TABLE 311: Africa Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 312: Africa Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 313: Africa 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030